The researchers suggested that Ashkenazi Jewish women as well as women of other ancestries might benefit from broader genetic screening for breast cancer risk.

The Bay Area startup has designed a menu of apps related to sleep, caffeine metabolism, and other indications.

Going forward, the company will focus on its wholly owned subsidiary Medicinal Genomics Corporation, which conducts cannabis genetics research.

Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.

The firm recently released two droplet digital PCR-based assays that can characterize edits generated by CRISPR-Cas9 or other genome editing tools.

While proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official.

The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals. 

Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.

Whatever practices you use for NGS assay development, validation, and performance monitoring, your goal is the same: Your results must be as accurate, precise, and consistent as possible.

That goal is within reach. And in this paper, we’ll show you how. By reading this white paper, you will learn:

· Why quality control is so challenging for NGS labs

· How reference materials may be the key to quality control

· The 9 key characteristics of sufficient NGS reference materials

· How to use QC metrics to monitor the health of your NGS assays

What’s been holding back more widespread adoption of liquid biopsy testing?

Lack of adequate circulating tumor DNA reference materials for developing and measuring safe, accurate and reproducible assays has been a challenge for clinical labs

Liquid biopsies are poised to revolutionize cancer diagnosis and therapy, but until now, advances in diagnostic technology - particularly at the low end of the sample input and sensitivity spectrum - have been hampered by the lack of ability of labs to reproducibly measure and assess the assay’s performance.